The Journal of Clinical Pharmacology
October 28, 2021
K W Smith, Dakota Sicignano, Adrían V. Hernández et al.
136 citations
MDMA-assisted psychotherapy reduces PTSD symptoms more than control therapy. Patients receiving MDMA showed a greater reduction in Clinician-Administered PTSD Scale scores (difference of –22.03; 95% CI, –38.53 to –5.52) and were 3.65 times more likely to achieve clinically significant symptom reductions (95% CI, 2.39–5.57). They were also 2.10 times more likely to no longer meet PTSD criteria (95% CI, 1.37–3.21). Common side effects include bruxism, anxiety, jitteriness, headache, and nausea. The therapy is generally safe and well tolerated, but unregulated MDMA or use outside a controlled therapeutic setting carries considerable risks.
The Journal of Clinical Pharmacology
May 19, 2011
Ichiro Ieiri, Yohei Doi, Kazuya Maeda et al.
106 citations
In 30 healthy volunteers matched for SLCO2B1 genotype, the effect of a genetic variant on the body's exposure to celiprolol depended on the dose. At a therapeutic dose (100 mg), people with two copies of the *3 variant had a lower average area under the concentration-time curve (AUC) of 775 ng·h/mL compared with 1097 ng·h/mL for those with one copy (*1/*3) and 1547 ng·h/mL for those with none (*1/*1). At a microdose (97.5 µg), these genotype differences disappeared. Dose-normalized AUC was much lower at the microdose, suggesting saturation of an efflux transporter at the therapeutic dose explains why the genetic effect only appears at that higher dose.
The Journal of Clinical Pharmacology
January 16, 2014
C. Michael White
58 citations
MDMA, used by over 16 million Americans, produces desired effects such as increased energy, elevated mood, bonding, and psychedelic experiences, but also carries risks including liver damage, depressed mood, serotonin syndrome, multiorgan failure, cardiovascular events, and death. Its effects stem from a pharmacologic profile combining methamphetamine-like and mescaline-like actions, plus increased release of cortisol, oxytocin, and antidiuretic hormone. The rave or electronic dance music environment—with warm temperatures, vigorous dancing, loud music, and light shows—accentuates both desirable responses and certain harms. Understanding these factors is essential for education, harm prevention, and treatment.
The Journal of Clinical Pharmacology
March 26, 2007
Joseph Bertino, Howard Greenberg, Michael D. Reed
51 citations
No Summary
The Journal of Clinical Pharmacology
August 1, 2021
Kristin Waters
18 citations
Hallucinogens are a diverse class of substances that alter thoughts, perceptions, and mood through various biological mechanisms. Classical hallucinogens like lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine act primarily on serotonin receptors, while others work through N-methyl-D-aspartate receptor antagonism, opioid receptor agonism, or inhibition of monoamine reuptake (serotonin, norepinephrine, dopamine). This article compares the pharmacologic similarities and differences among hallucinogens and reviews their physical and psychiatric effects, including potential life-threatening and long-term toxicities.
The Journal of Clinical Pharmacology
August 9, 1980
Balkrishena Kaul, Bernard Davidow
3 citations
A radioimmunoassay procedure was developed to detect phencyclidine (PCP) intoxication. In 11 patients with symptoms including violent behavior, delusions, hallucinations, and agitation, serum PCP concentrations in five subjects ranged from 0.5 to 40 ng/ml. For laboratory confirmation, ascorbic acid should be administered after collecting the initial urine specimen; the first or second postacidification urine often identified PCP when the initial specimen was negative or questionable. Patients in emergency rooms with hallucinations and a history of marijuana use should be screened for PCP; if negative, other hallucinogens such as LSD, ketamine, mescaline, or psilocybin may be suspected.